Woman faces risk of rare spinal condition after yoga pose led to slipped discs
Doctors told a U.K. woman she's at risk of developing a rare spinal condition due to a yoga pose she did years ago, according to news agency SWNS.
Terrilyn Griffiths, 44, from Lowestoft, Suffolk, exhibited early signs of cauda equina syndrome (CES, a dangerous form of spinal nerve damage) in January 2024 when an MRI revealed slipped discs in her back, stemming from yoga-induced back injuries.
"I was showing my ex's kids how to do a standing bridge pose when my back gave way," she said of the initial incident in 2021.
At first, Griffiths "thought nothing of it," but then she began experiencing back pain two weeks later, often feeling like she "would collapse at the waist."
"It didn't help that I worked a laborious job, and I had to carry heavy materials around all day," Griffiths, who worked in a factory at the time, told SWNS.
She pushed through the pain for six months until it subsided, leading her to think it had eventually "healed on its own."
But the pain resurfaced almost two years later in June 2023. "I had a physical week at work, and my back went right before I had a horse-riding lesson," she said.
Griffiths eventually went to the doctor in January 2024, when she learned she had early signs of cauda equina syndrome, which can cause pain, weakness and incontinence, per Cleveland Clinic.
"CES is traumatic and life-changing … it has taken my life away."
Doctors referred the woman to a physiotherapist, but Griffith said "nothing has helped." She is not eligible for a corrective surgery because she doesn't present any "red flag symptoms" characteristic of the condition.
During this time, Griffiths was experiencing dexterity issues in her hands, weakness in her hip and groin area, altered sensation in her saddle region and a semi-paralyzed bladder, per the SWNS report.
She also "struggles to walk" and is unable to travel more than a single flight of stairs without having pins and needles.
After working with the physiotherapist for nine months doing small exercises, Griffiths said the pain across her back only got worse.
"CES is traumatic and life-changing," said Griffiths, who is now housebound.
"Not many people seem to know much about it, which has made getting the right treatment harder … and now it has taken my life away."
"I feel as if there's little hope for me in the future," she added.
According to the U.K.'s National Health Service, if the condition is not addressed early, it can result in life-changing injuries.
Griffiths is now raising funds for private consultations, travel expenses and support at home.
For more Health articles, visit www.foxnews.com/health
"I have started looking into getting the surgical procedure elsewhere — maybe abroad — to decompress the area," she said. "But I wish more people were more aware of incomplete and partial cauda equina syndrome."
"Perhaps things would have been different for me."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
England is launching a gonorrhea vaccine. Is Canada next?
England will soon begin administering a vaccine to high-risk individuals that may reduce their chances of contracting gonorrhea, but a similar program is not yet in the cards for Canada. According to studies cited by England's National Health Service, the 4CMenB vaccine, which is presently used in Canada for immunization against meningitis B, has an effectiveness of 32.7 to 42 per cent against gonorrhea. To combat rising infection rates, the health service said last month it will begin administering the vaccine free of charge in August for those deemed to be at high risk of contracting gonorrhea, including gay and bisexual men who have a history of sexually transmitted infection or multiple sex partners. But the vaccine has not been authorized for this use in Canada, even as cases of gonorrhea continue to rise across the country. According to the most recent national statistics, rates of the sexually transmitted infection more than tripled in Canada from 2010 to 2022, going from 11,381 in 2010 to 35,956 in 2022. Gonorrhea, often referred to as "the clap," is passed on through oral, anal or genital sex. People who've been infected, especially women, often show no symptoms at all. If left untreated, it can have serious health risks. In an interview with CBC News on Monday, Calgary physician Caley Shukalek, the chief medical officer for Freddie, an online service that focuses on 2SLGBTQ+ health care, said it's still too soon to know how effective the 4CMenB vaccine will be at preventing new gonorrhea infections. Early research hasn't been conclusive either, Shukalek said, citing another study conducted by researchers in France that suggested the vaccine may not have any statistical effect on gonorrhea rates. "I think in the medical community, there's still a bit of skepticism," he said, noting that more research needs to be done before the true impact is known. The potential upside is promising enough, however, that Shukalek said he has begun prescribing the vaccine to some people who are willing to pay for it out of pocket or through private health insurance. "Its safety is very well established, so for those at high risk of STIs, I think this is a very worthwhile thing and something that could be considered," he said. "But because it's kind of what we call off-label, it absolutely is something that needs to be a discussion between a prescriber and a patient to make sure that it's the right decision based on their individual risk." The vaccine is typically administered in two phases, he said, with the second dose coming at least four weeks after the first. Chris Aucoin is the executive director of the Health Equity Alliance of Nova Scotia, a group that advocates for those living with HIV and members of the 2SLGBTQ+ community. He's aware of the latest research on the use of the 4CMenB vaccine to help prevent the spread of gonorrhea, but notes that even if it's approved, it would only be one part of a potential prevention strategy. Aucoin said the best thing people can do now and in the future to prevent the spread of gonorrhea is to get tested regularly. "If people are concerned about gonorrhea rates, which are too high … the biggest factor in that for me is the fact that people don't test regularly enough." He said the recent launch of Nova Scotia's STI Care Now program, which mails out free at-home testing kits for chlamydia, gonorrhea and HIV to anyone interested across the province, is a positive step toward making this easier. "We now have a tool that's accessible to them in a way that's never been the case in Nova Scotia," he said. In a statement, the Public Health Agency of Canada said the National Advisory Committee on Immunization is monitoring the latest research on the 4CMenB vaccine. In a 2023 report, the advisory committee noted that although the vaccine is not currently authorized for this purpose, it may "offer some level of cross-protection against gonococcal infection." The agency said it expects the committee to further assess this possibility as more evidence becomes available. Nova Scotia's Department of Health and Wellness echoed this statement, noting that it takes its cues on immunization from the committee Those looking to pay out of pocket for the vaccine in the private market would be looking at around $200 per dose, the department said. In 2024, there were 368 new cases of gonorrhea reported in Nova Scotia. MORE TOP STORIES
Medscape
7 hours ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.
Medscape
7 hours ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
